Congressional Briefing Helps Debunk "Windfall" Argument of Device Tax
New research shows that despite providing near-universal health care coverage in the state of Massachusetts, the overwhelming percentage of medical device companies saw no increases in utilization, and in turn profits. This new data helps debunk the main argument for supporters of the 2.3 % medical device excise tax.
The report was detailed in a Congressional briefing hosted by CONNECT.
Alex Lukianov, MDMA Board member and Chairman & Chief Executive Officer of NuVasive, Inc, and Matthew Dolan, Senior Research Analyst at ROTH Capital Partners LLC, detailed the challenges that face the med tech ecosystem at the briefing, and why repealing the medical device tax is so important.
The event was an opportunity for Capitol Hill staff and Washington media to learn more about the industry, and get updates about the current environment.